5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 2.23▲ | 2.23▲ | 2.25▼ | 2.29▼ | 2.13▲ |
MA10 | 2.25▼ | 2.28▼ | 2.28▼ | 2.32▼ | 1.93▲ |
MA20 | 2.29▼ | 2.28▼ | 2.28▼ | 2.11▲ | 1.83▲ |
MA50 | 2.30▼ | 2.30▼ | 2.31▼ | 1.81▲ | 2.04▲ |
MA100 | 2.31▼ | 2.28▼ | 2.16▲ | 1.80▲ | N/A |
MA200 | 2.30▼ | 2.11▲ | 1.93▲ | 2.11▲ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.008▼ | -0.009▼ | -0.008▼ | -0.001▼ | N/A |
RSI | 34.476▼ | 40.032▼ | 42.784▼ | 57.648▲ | N/A |
STOCH | 8.553▼ | 11.467▼ | 29.962 | 56.405 | 69.310 |
WILL %R | -83.333▼ | -85.185▼ | -85.185▼ | -43.174 | -25.980 |
CCI | -51.192 | -82.694 | -102.083▼ | 16.925 | 115.647▲ |
Monday, January 11, 2021 10:46 PM
Exicure, Inc. (NASDAQ:XCUR) has been given a consensus recommendation of “Buy” by the six ratings firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has ...
|
Monday, January 11, 2021 09:00 AM
Exicure announced that the U.S. FDA has granted Fast Track designations for cavrotolimod (AST-008) for two development programs.
|
Sunday, January 10, 2021 04:00 PM
The MarketWatch News Department was not involved in the creation of this content. Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
25/01/21 | 2.31 | 2.31 | 2.215 | 2.235 | 298,208 |
22/01/21 | 2.28 | 2.35 | 2.23 | 2.33 | 329,976 |
21/01/21 | 2.35 | 2.38 | 2.23 | 2.31 | 597,676 |
20/01/21 | 2.28 | 2.42 | 2.26 | 2.27 | 592,614 |
19/01/21 | 2.47 | 2.4829 | 2.165 | 2.28 | 981,512 |
15/01/21 | 2.50 | 2.5351 | 2.25 | 2.31 | 621,704 |
14/01/21 | 2.3938 | 2.53 | 2.32 | 2.50 | 611,858 |
13/01/21 | 2.23 | 2.45 | 2.17 | 2.40 | 700,500 |
12/01/21 | 2.21 | 2.25 | 2.075 | 2.25 | 679,894 |
11/01/21 | 2.12 | 2.45 | 2.07 | 2.30 | 1,712,122 |
|
|
||||
|
|
||||
|
|